UniProt Q9L5C8
beta-lactamase CTX-M-9 (Q9L5C8)
beta-lactamase CTX-M-9 (UniProt Q9L5C8), EC 3.5.2.6: 54 experimental structures on GenesisL1, 9 ligands bound, 12 pockets. Binding sites, pockets, druggability and 3D structures in GL1X.
- UniProt
- Q9L5C8
- Protein
- beta-lactamase CTX-M-9
- EC
- 3.5.2.6
- Experimental structures
- 54
- Predicted models
- 0
- Ligands
- 9
- Pockets
- 12 · 1 record with a druggable one
Structures
54 records of Q9L5C8 in the MolNFT archive: 54 experimental, 0 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 1YLJ | Atomic resolution structure of CTX-M-9 beta-lactamase | x-ray diffraction | A | GLC, FRU, SO4 | 1 (best 0.34) |
| 1YLJ | Atomic resolution structure of ctx-M-9 beta-lactamase | x-ray diffraction | A | — | — |
| 1YM1 | X-ray crystallographic structure of CTX-M-9 beta-lactamase complexed with a boronic acid inhibitor… | x-ray diffraction | A, B | PO4, SM2 | 2 (best 0.29) |
| 1YM1 | X-ray crystallographic structure of ctx-M-9 beta-lactamase complexed with a boronic acid inhibitor… | x-ray diffraction | A, B | — | — |
| 1YMS | X-ray crystallographic structure of CTX-M-9 beta-lactamase complexed with nafcinin-like boronic… | x-ray diffraction | A, B | NBF | 2 (best 0.38) |
| 1YMS | X-ray crystallographic structure of ctx-M-9 beta-lactamase complexed with nafcinin-like boronic… | x-ray diffraction | A, B | — | — |
| 1YMX | X-ray crystallographic structure of CTX-M-9 beta-lactamase covalently linked to cefoxitin | x-ray diffraction | A, B | 1QL | 2 (best 0.32) |
| 1YMX | X-ray crystallographic structure of ctx-M-9 beta-lactamase covalently linked to cefoxitin | x-ray diffraction | A, B | — | — |
| 2P74 | CTX-M-9 class A beta-lactamase apo crystal structure at 0.88 Angstrom resolution | x-ray diffraction | A, B | — | — |
| 2P74 | Ctx-M-9 class a beta-lactamase apo crystal structure at 0.88 ångström resolution | x-ray diffraction | A, B | — | — |
| 3G2Y | CTX-M-9 class A beta-lactamase complexed with compound 1 (GF4) | x-ray diffraction | A, B | — | — |
| 3G2Y | Ctx-M-9 class a beta-lactamase complexed with compound 1 (GF4) | x-ray diffraction | A, B | — | — |
| 3G2Z | CTX-M-9 class A beta-lactamase complexed with compound 2 (GZ2) | x-ray diffraction | A, B | — | — |
| 3G2Z | Ctx-M-9 class a beta-lactamase complexed with compound 2 (GZ2) | x-ray diffraction | A, B | — | — |
| 3G30 | CTX-M-9 class A beta-lactamase complexed with compound 3 (G30) | x-ray diffraction | A | — | — |
| 3G30 | Ctx-M-9 class a beta-lactamase complexed with compound 3 (G30) | x-ray diffraction | A | — | — |
| 3G31 | CTX-M-9 class A beta-lactamase complexed with compound 4 (GF1) | x-ray diffraction | A, B | — | — |
| 3G31 | Ctx-M-9 class a beta-lactamase complexed with compound 4 (GF1) | x-ray diffraction | A, B | — | — |
| 3G32 | CTX-M-9 class A beta-lactamase complexed with compound 6 (3G3) | x-ray diffraction | A, B | — | — |
| 3G32 | Ctx-M-9 class a beta-lactamase complexed with compound 6 (3G3) | x-ray diffraction | A, B | — | — |
| 3G34 | CTX-M-9 class A beta-lactamase complexed with compound 11 (1CE) | x-ray diffraction | A, B | — | — |
| 3G34 | Ctx-M-9 class a beta-lactamase complexed with compound 11 (1CE) | x-ray diffraction | A, B | — | — |
| 3G35 | CTX-M-9 class A beta-lactamase complexed with compound 12 (F13) | x-ray diffraction | A, B | — | — |
| 3G35 | Ctx-M-9 class a beta-lactamase complexed with compound 12 (F13) | x-ray diffraction | A, B | — | — |
| 3HLW | CTX-M-9 S70G in complex with cefotaxime | x-ray diffraction | A, B | — | — |
| 3HLW | Ctx-M-9 S70G in complex with cefotaxime | x-ray diffraction | A, B | — | — |
| 3HRE | X-ray crystallographic structure of CTX-M-9 S70G | x-ray diffraction | A, B | — | — |
| 3HRE | X-ray crystallographic structure of ctx-M-9 S70G | x-ray diffraction | A, B | — | — |
| 3HUO | X-ray crystallographic structure of CTX-M-9 S70G in complex with benzylpenicillin | x-ray diffraction | A, B | — | — |
| 3HUO | X-ray crystallographic structure of ctx-M-9 S70G in complex with benzylpenicillin | x-ray diffraction | A, B | — | — |
| 3HVF | X-ray crystallographic structure of CTX-M-9 S70G in complex with hydrolyzed benzylpenicillin | x-ray diffraction | A, B | — | — |
| 3HVF | X-ray crystallographic structure of ctx-M-9 S70G in complex with hydrolyzed benzylpenicillin | x-ray diffraction | A, B | — | — |
| 3Q07 | CTX-M-9 S70G in complex with piperacillin | x-ray diffraction | A, B | — | — |
| 3Q07 | Ctx-M-9 S70G in complex with piperacillin | x-ray diffraction | A, B | — | — |
| 3Q1F | CTX-M-9 S70G in complex with hydrolyzed piperacillin | x-ray diffraction | A, B | — | — |
| 3Q1F | Ctx-M-9 S70G in complex with hydrolyzed piperacillin | x-ray diffraction | A, B | — | — |
| 4DDS | CTX-M-9 class A beta-lactamase complexed with compound 11 | x-ray diffraction | A, B | — | — |
| 4DDS | Ctx-M-9 class a beta-lactamase complexed with compound 11 | x-ray diffraction | A, B | — | — |
| 4DDY | CTX-M-9 class A beta-lactamase complexed with compound 10 | x-ray diffraction | A, B | — | — |
| 4DDY | Ctx-M-9 class a beta-lactamase complexed with compound 10 | x-ray diffraction | A, B | — | — |
| 4DE0 | CTX-M-9 class A beta-lactamase complexed with compound 16 | x-ray diffraction | A, B | — | — |
| 4DE0 | Ctx-M-9 class a beta-lactamase complexed with compound 16 | x-ray diffraction | A, B | — | — |
| 4DE1 | CTX-M-9 class A beta-lactamase complexed with compound 18 | x-ray diffraction | A, B | — | — |
| 4DE1 | Ctx-M-9 class a beta-lactamase complexed with compound 18 | x-ray diffraction | A, B | — | — |
| 4DE2 | CTX-M-9 class A beta-lactamase complexed with compound 12 | x-ray diffraction | A, B | — | — |
| 4DE2 | Ctx-M-9 class a beta-lactamase complexed with compound 12 | x-ray diffraction | A, B | — | — |
| 4DE3 | CTX-M-9 class A beta-lactamase complexed with compound 4 | x-ray diffraction | A, B | — | — |
| 4DE3 | Ctx-M-9 class a beta-lactamase complexed with compound 4 | x-ray diffraction | A, B | — | — |
| 4LEN | CTX-M-9 in complex with the broad spectrum inhibitor 3-(2- carboxyvinyl)benzo(b)thiophene-2-boronic… | x-ray diffraction | A, B | — | — |
| 4LEN | Ctx-M-9 in complex with the broad spectrum inhibitor 3-(2- CARBOXYVINYL)BENZO(B)THIOPHENE-2-boronic… | x-ray diffraction | A, B | — | — |
| 5KMT | CTX-M9 mutant L48A | x-ray diffraction | A, B | PO4, K | 5 (best 0.51) |
| 5KMT | Ctx-M9 mutant L48A | x-ray diffraction | A, B | PO4, K | — |
| 5KMU | CTX-M-9 beta lactamase mutant - T165W | x-ray diffraction | A | PO4, CL | — |
| 5KMU | Ctx-M-9 beta lactamase mutant - T165W | x-ray diffraction | A | PO4, CL | — |
Ligands
- PO4 · Phosphate ion · in 5 records
- CL · Chloride ion · in 2 records
- K · Potassium ion · in 2 records
- 1QL · (2R)-5-[(carbamoyloxy)methyl]-2-{(1S)-1-methoxy-2-oxo-1-[(thiophen-2-ylacetyl)amino]ethyl}-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid · in 1 record
- FRU · beta-D-fructofuranose · in 1 record
- GLC · alpha-D-glucopyranose · in 1 record
- NBF · [(2-ethoxy-1-naphthoyl)amino]methylboronic acid · in 1 record
- SM2 · (1R)-1-(2-thienylacetylamino)-1-(3-carboxyphenyl) methylboronic acid · in 1 record
- SO4 · Sulfate ion · in 1 record
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.